menu
    • menu
    [{"orgOrder":0,"company":"Veristat","sponsor":"PreveCeutical Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Veristat \/ PreveCeutical","highestDevelopmentStatusID":"4","companyTruncated":"Veristat \/ PreveCeutical"},{"orgOrder":0,"company":"Veristat","sponsor":"Antibe Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Larimar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CTI-1601","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Larimar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Veristat \/ Veristat, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat, Inc."},{"orgOrder":0,"company":"Veristat","sponsor":"Dicerna Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veristat \/ Veristat Inc","highestDevelopmentStatusID":"10","companyTruncated":"Veristat \/ Veristat Inc"},{"orgOrder":0,"company":"Veristat","sponsor":"Larimar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Veristat \/ Veristat, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat, Inc."},{"orgOrder":0,"company":"Veristat","sponsor":"Laboratorios HIPRA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Protein Covid-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"12","companyTruncated":"Veristat \/ Veristat"}]

    Find Clinical Drug Pipeline Developments & Deals by Veristat

    Menu

    Veristat

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Protein Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Laboratorios HIPRA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine

                            Details : Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, ag...

                            Brand Name : Bimervax

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 25, 2023

                            Lead Product(s) : Recombinant Protein Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Laboratorios HIPRA

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTI-1601

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

                            Details : CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein.

                            Brand Name : CTI-1601

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 14, 2022

                            Lead Product(s) : CTI-1601

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nedosiran

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Dicerna Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment...

                            Details : Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p<0.0001).

                            Brand Name : DCR-PHXC

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 05, 2021

                            Lead Product(s) : Nedosiran

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Dicerna Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTI-1601

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Place...

                            Details : CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein.

                            Brand Name : CTI-1601

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 25, 2021

                            Lead Product(s) : CTI-1601

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTI-1601

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Larimar Reports Positive Topline Phase 1 Data Showing Dose-Dependent Increases in Frataxin Levels in Patients ...

                            Details : Data show that repeated subcutaneous administration of CTI-1601 resulted in dose-dependent increases in frataxin (FXN) levels from baseline compared to placebo controls.

                            Brand Name : CTI-1601

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 11, 2021

                            Lead Product(s) : CTI-1601

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Antibe Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain

                            Details : Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin.

                            Brand Name : ATB-346

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 29, 2021

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Antibe Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : PreveCeutical Medical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program

                            Details : Under the terms of the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical program and write the required protocol.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 04, 2020

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : PreveCeutical Medical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth